Comparing measurement properties of EQ-5D-Y-3L and EQ-5D-Y-5L in paediatric patients

Titi Sahidah Fitriana; Fredrick Dermawan Purba; Rina Rahmatika; Riski Muhaimin; Nur Melani Sari; Gouke Bonsel; Elly Stolk; Jan J.V. Busschbach

doi:10.1186/s12955-021-01889-4

Comparing measurement properties of EQ-5D-Y-3L and EQ-5D-Y-5L in paediatric patients

Titi Sahidah Fitriana^*, Fredrick Dermawan Purba, Rina Rahmatika, Riski Muhaimin, Nur Melani Sari, Gouke Bonsel, Elly Stolk, Jan J.V. Busschbach

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

9 Citations (Scopus)

7 Downloads (Pure)

Abstract

Background: The adult versions EQ-5D-3L and EQ-5D-5L have been extensive compared. This is not the case for the EQ-5D youth versions. The study aim was to compare the measurement properties and responsiveness of EQ-5D-Y-3L and EQ-5D-Y-5L in paediatric patients. Methods: A sample of patients 8–16 years old with different diseases and a wide range of disease severity was asked to complete EQ-5D-Y-3L, EQ-5D-Y-5L, PedsQL Generic Core Scale, and selected, appropriate disease-specific instruments, three times. EQ-5D-Y-3L and EQ-5D-Y-5L were compared in terms of: feasibility, (re-)distribution properties, discriminatory power, convergent validity, test–retest reliability, and responsiveness. Results: 286 participating patients suffered from one of the following diseases: major beta-thalassemia, haemophilia, acute lymphoblastic leukaemia, acute illness. Missing responses were comparable between versions of the EQ-5D-Y, suggesting comparable feasibility. The number of patients in the best health state (level profile 11111) was equal in both EQ-5D-Y versions. The projection of EQ-5D-Y-3L scores onto EQ-5D-Y-5L for all dimensions showed that the two additional levels in EQ-5D-Y-5L slightly improved the accuracy of patients in reporting their problems, especially if severe. Convergent validity with PedsQL and disease-specific measures showed that the two EQ-5D-Y versions performed about equally. Test–retest reliability (EQ-5D-Y-3L 0.78 vs EQ-5D-Y-5L 0.84), and sensitivity for detecting health changes, were both better in EQ-5D-Y-5L. Conclusions: Extending the number of levels did not give clear superiority to EQ-5D-Y-5L over EQ-5D-Y-3L based on the criteria assessed in this study. However, increasing the number of levels benefitted EQ-5D-Y performance in the measurement of moderate to severe problems and especially in longitudinal study designs.

Original language	English
Article number	256
Journal	Health and Quality of Life Outcomes
Volume	19
Issue number	1
DOIs	https://doi.org/10.1186/s12955-021-01889-4
Publication status	Published - 15 Nov 2021

Bibliographical note

Funding Information:
Funding for this study was provided by the EuroQol Group grant EQ Project 20180140 and Indonesian Endowment Fund for Education (LPDP). Both grants were unrestricted.

Funding Information:
We would like to thank Mimmi ?str?m for her valuable input, and all those who provided helpful comments at the 2019 EuroQol Plenary Meeting. High appreciation is also given to the 5 participating hospitals (Dharmais Cancer Hospital, Cipto Mangunkusumo Hospital, Islamic Hospital, Hermina Kemayoran Hospital, and Hasan Sadikin Hospital), and to all the hard-working interviewers, especially Putri Andine and Cindi Anggraini.

Publisher Copyright:
© 2021, The Author(s).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/s12955-021-01889-4Licence: CC BY

Comparing measurement properties of EQ-5D-Y-3L and EQ-5D-Y-5L in paediatric patientsFinal published version, 1.07 MBLicence: CC BY

Cite this

@article{23a9d6f69fb043c698de2e8363275829,

title = "Comparing measurement properties of EQ-5D-Y-3L and EQ-5D-Y-5L in paediatric patients",

abstract = "Background: The adult versions EQ-5D-3L and EQ-5D-5L have been extensive compared. This is not the case for the EQ-5D youth versions. The study aim was to compare the measurement properties and responsiveness of EQ-5D-Y-3L and EQ-5D-Y-5L in paediatric patients. Methods: A sample of patients 8–16 years old with different diseases and a wide range of disease severity was asked to complete EQ-5D-Y-3L, EQ-5D-Y-5L, PedsQL Generic Core Scale, and selected, appropriate disease-specific instruments, three times. EQ-5D-Y-3L and EQ-5D-Y-5L were compared in terms of: feasibility, (re-)distribution properties, discriminatory power, convergent validity, test–retest reliability, and responsiveness. Results: 286 participating patients suffered from one of the following diseases: major beta-thalassemia, haemophilia, acute lymphoblastic leukaemia, acute illness. Missing responses were comparable between versions of the EQ-5D-Y, suggesting comparable feasibility. The number of patients in the best health state (level profile 11111) was equal in both EQ-5D-Y versions. The projection of EQ-5D-Y-3L scores onto EQ-5D-Y-5L for all dimensions showed that the two additional levels in EQ-5D-Y-5L slightly improved the accuracy of patients in reporting their problems, especially if severe. Convergent validity with PedsQL and disease-specific measures showed that the two EQ-5D-Y versions performed about equally. Test–retest reliability (EQ-5D-Y-3L 0.78 vs EQ-5D-Y-5L 0.84), and sensitivity for detecting health changes, were both better in EQ-5D-Y-5L. Conclusions: Extending the number of levels did not give clear superiority to EQ-5D-Y-5L over EQ-5D-Y-3L based on the criteria assessed in this study. However, increasing the number of levels benefitted EQ-5D-Y performance in the measurement of moderate to severe problems and especially in longitudinal study designs.",

author = "Fitriana, {Titi Sahidah} and Purba, {Fredrick Dermawan} and Rina Rahmatika and Riski Muhaimin and Sari, {Nur Melani} and Gouke Bonsel and Elly Stolk and Busschbach, {Jan J.V.}",

note = "Funding Information: Funding for this study was provided by the EuroQol Group grant EQ Project 20180140 and Indonesian Endowment Fund for Education (LPDP). Both grants were unrestricted. Funding Information: We would like to thank Mimmi ?str?m for her valuable input, and all those who provided helpful comments at the 2019 EuroQol Plenary Meeting. High appreciation is also given to the 5 participating hospitals (Dharmais Cancer Hospital, Cipto Mangunkusumo Hospital, Islamic Hospital, Hermina Kemayoran Hospital, and Hasan Sadikin Hospital), and to all the hard-working interviewers, especially Putri Andine and Cindi Anggraini. Publisher Copyright: {\textcopyright} 2021, The Author(s).",

year = "2021",

month = nov,

day = "15",

doi = "10.1186/s12955-021-01889-4",

language = "English",

volume = "19",

journal = "Health and Quality of Life Outcomes",

issn = "1477-7525",

publisher = "BioMed Central Ltd.",

number = "1",

}

TY - JOUR

T1 - Comparing measurement properties of EQ-5D-Y-3L and EQ-5D-Y-5L in paediatric patients

AU - Fitriana, Titi Sahidah

AU - Purba, Fredrick Dermawan

AU - Rahmatika, Rina

AU - Muhaimin, Riski

AU - Sari, Nur Melani

AU - Bonsel, Gouke

AU - Stolk, Elly

AU - Busschbach, Jan J.V.

N1 - Funding Information: Funding for this study was provided by the EuroQol Group grant EQ Project 20180140 and Indonesian Endowment Fund for Education (LPDP). Both grants were unrestricted. Funding Information: We would like to thank Mimmi ?str?m for her valuable input, and all those who provided helpful comments at the 2019 EuroQol Plenary Meeting. High appreciation is also given to the 5 participating hospitals (Dharmais Cancer Hospital, Cipto Mangunkusumo Hospital, Islamic Hospital, Hermina Kemayoran Hospital, and Hasan Sadikin Hospital), and to all the hard-working interviewers, especially Putri Andine and Cindi Anggraini. Publisher Copyright: © 2021, The Author(s).

PY - 2021/11/15

Y1 - 2021/11/15

N2 - Background: The adult versions EQ-5D-3L and EQ-5D-5L have been extensive compared. This is not the case for the EQ-5D youth versions. The study aim was to compare the measurement properties and responsiveness of EQ-5D-Y-3L and EQ-5D-Y-5L in paediatric patients. Methods: A sample of patients 8–16 years old with different diseases and a wide range of disease severity was asked to complete EQ-5D-Y-3L, EQ-5D-Y-5L, PedsQL Generic Core Scale, and selected, appropriate disease-specific instruments, three times. EQ-5D-Y-3L and EQ-5D-Y-5L were compared in terms of: feasibility, (re-)distribution properties, discriminatory power, convergent validity, test–retest reliability, and responsiveness. Results: 286 participating patients suffered from one of the following diseases: major beta-thalassemia, haemophilia, acute lymphoblastic leukaemia, acute illness. Missing responses were comparable between versions of the EQ-5D-Y, suggesting comparable feasibility. The number of patients in the best health state (level profile 11111) was equal in both EQ-5D-Y versions. The projection of EQ-5D-Y-3L scores onto EQ-5D-Y-5L for all dimensions showed that the two additional levels in EQ-5D-Y-5L slightly improved the accuracy of patients in reporting their problems, especially if severe. Convergent validity with PedsQL and disease-specific measures showed that the two EQ-5D-Y versions performed about equally. Test–retest reliability (EQ-5D-Y-3L 0.78 vs EQ-5D-Y-5L 0.84), and sensitivity for detecting health changes, were both better in EQ-5D-Y-5L. Conclusions: Extending the number of levels did not give clear superiority to EQ-5D-Y-5L over EQ-5D-Y-3L based on the criteria assessed in this study. However, increasing the number of levels benefitted EQ-5D-Y performance in the measurement of moderate to severe problems and especially in longitudinal study designs.

AB - Background: The adult versions EQ-5D-3L and EQ-5D-5L have been extensive compared. This is not the case for the EQ-5D youth versions. The study aim was to compare the measurement properties and responsiveness of EQ-5D-Y-3L and EQ-5D-Y-5L in paediatric patients. Methods: A sample of patients 8–16 years old with different diseases and a wide range of disease severity was asked to complete EQ-5D-Y-3L, EQ-5D-Y-5L, PedsQL Generic Core Scale, and selected, appropriate disease-specific instruments, three times. EQ-5D-Y-3L and EQ-5D-Y-5L were compared in terms of: feasibility, (re-)distribution properties, discriminatory power, convergent validity, test–retest reliability, and responsiveness. Results: 286 participating patients suffered from one of the following diseases: major beta-thalassemia, haemophilia, acute lymphoblastic leukaemia, acute illness. Missing responses were comparable between versions of the EQ-5D-Y, suggesting comparable feasibility. The number of patients in the best health state (level profile 11111) was equal in both EQ-5D-Y versions. The projection of EQ-5D-Y-3L scores onto EQ-5D-Y-5L for all dimensions showed that the two additional levels in EQ-5D-Y-5L slightly improved the accuracy of patients in reporting their problems, especially if severe. Convergent validity with PedsQL and disease-specific measures showed that the two EQ-5D-Y versions performed about equally. Test–retest reliability (EQ-5D-Y-3L 0.78 vs EQ-5D-Y-5L 0.84), and sensitivity for detecting health changes, were both better in EQ-5D-Y-5L. Conclusions: Extending the number of levels did not give clear superiority to EQ-5D-Y-5L over EQ-5D-Y-3L based on the criteria assessed in this study. However, increasing the number of levels benefitted EQ-5D-Y performance in the measurement of moderate to severe problems and especially in longitudinal study designs.

UR - http://www.scopus.com/inward/record.url?scp=85119043448&partnerID=8YFLogxK

U2 - 10.1186/s12955-021-01889-4

DO - 10.1186/s12955-021-01889-4

M3 - Article

AN - SCOPUS:85119043448

SN - 1477-7525

VL - 19

JO - Health and Quality of Life Outcomes

JF - Health and Quality of Life Outcomes

IS - 1

M1 - 256

ER -

Comparing measurement properties of EQ-5D-Y-3L and EQ-5D-Y-5L in paediatric patients

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this